On Friday, Spyre Therapeutics Inc (NASDAQ: SYRE) was -6.65% drop from the session before settling in for the closing price of $32.76. A 52-week range for SYRE has been $10.91 – $35.31.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 44.65%. When this article was written, the company’s average yearly earnings per share was at 35.15%. With a float of $67.52 million, this company’s outstanding shares have now reached $77.59 million.
Spyre Therapeutics Inc (SYRE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 12.99%, while institutional ownership is 77.23%. The most recent insider transaction that took place on Dec 01 ’25, was worth 435,356. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $29.02, taking the stock ownership to the 686,907 shares. Before that another transaction happened on Nov 03 ’25, when Company’s Chief Executive Officer sold 45,000 for $23.33, making the entire transaction worth $1,049,778. This insider now owns 701,907 shares in total.
Spyre Therapeutics Inc (SYRE) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.81 earnings per share (EPS) during the time that was better than consensus figure (set at -0.94) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.65% during the next five years compared to 44.65% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
As of the previous 9 days, the stock’s Stochastic %D was 28.46%.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 77.27%, which indicates a significant increase from 9.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.56 in the past 14 days, which was higher than the 1.30 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.21, while its 200-day Moving Average is $19.12. Now, the first resistance to watch is $32.56. This is followed by the second major resistance level at $34.53. The third major resistance level sits at $35.76. If the price goes on to break the first support level at $29.36, it is likely to go to the next support level at $28.13. Assuming the price breaks the second support level, the third support level stands at $26.16.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
There are 77,592K outstanding shares of the company, which has a market capitalization of 2.37 billion. As of now, sales total 0 K while income totals -208,020 K. Its latest quarter income was 0 K while its last quarter net income were -11,180 K.
